Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,532.40
(
0.00%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
93.52
(
2.36%
)
Bitcoin
72,839.02
(
-0.97%
)
News Focus
News Focus
Post# of 257665
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 217266

Wednesday, 02/14/2018 8:14:52 AM

Wednesday, February 14, 2018 8:14:52 AM

Post# of 257665
NKTR-214 is absolutely worth the price BMY is paying, IMO. Anecdotal info from the Opdivo/NKTR-214 sarcoma IST has some patients with Stage-IV disease obtaining long-lasting responses. NKTR has cited this trial as a possible quick path to FDA approval due to the unmet medical need in sarcoma.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now